- Home
- HIND vs SABS Comparison
HIND vs SABS Comparison
Compare HIND & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | SABS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 31.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIND | SABS |
|---|---|---|
| Price | $4.85 | $3.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | N/A | ★ 254.7K |
| Earning Date | N/A | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.00 |
| 52 Week High | N/A | $6.60 |
Technical Indicators
Market Signals| Indicator | HIND | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 55.33 |
| Support Level | $4.80 | $3.30 |
| Resistance Level | $5.88 | $4.08 |
| Average True Range (ATR) | 0.43 | 0.31 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 30.56 | 51.69 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.